| First Author | Leal-Junior EC | Year | 2014 |
| Journal | PLoS One | Volume | 9 |
| Issue | 3 | Pages | e89453 |
| PubMed ID | 24599021 | Mgi Jnum | J:215130 |
| Mgi Id | MGI:5604691 | Doi | 10.1371/journal.pone.0089453 |
| Citation | Leal-Junior EC, et al. (2014) Superpulsed low-level laser therapy protects skeletal muscle of mdx mice against damage, inflammation and morphological changes delaying dystrophy progression. PLoS One 9(3):e89453 |
| abstractText | AIM: To evaluate the effects of preventive treatment with low-level laser therapy (LLLT) on progression of dystrophy in mdx mice. METHODS: Ten animals were randomly divided into 2 experimental groups treated with superpulsed LLLT (904 nm, 15 mW, 700 Hz, 1 J) or placebo-LLLT at one point overlying the tibialis anterior muscle (bilaterally) 5 times per week for 14 weeks (from 6th to 20th week of age). Morphological changes, creatine kinase (CK) activity and mRNA gene expression were assessed in animals at 20th week of age. RESULTS: Animals treated with LLLT showed very few morphological changes in skeletal muscle, with less atrophy and fibrosis than animals treated with placebo-LLLT. CK was significantly lower (p=0.0203) in animals treated with LLLT (864.70 U.l-1, SEM 226.10) than placebo (1708.00 U.l-1, SEM 184.60). mRNA gene expression of inflammatory markers was significantly decreased by treatment with LLLT (p<0.05): TNF-alpha (placebo-control=0.51 microg/microl [SEM 0.12], - LLLT=0.048 microg/microl [SEM 0.01]), IL-1beta (placebo-control=2.292 microg/microl [SEM 0.74], - LLLT=0.12 microg/microl [SEM 0.03]), IL-6 (placebo-control=3.946 microg/microl [SEM 0.98], |
